Regeneron Q2 2026: Revenue Jumps 17% to $4.3B, EPS Crushes Estimates, Dupixent Reaches $6B
REGN sits 33% above its 52-week low of $541.
Summary
Regeneron crushed Q2 2026 estimates with $4.29B in revenue (up 17% YoY) and non-GAAP EPS of $14.29, driven by record Dupixent, EYLEA HD, and Libtayo sales. The Sanofi Development Balance is fully repaid, boosting future profits, and full-year guidance was raised.
Updates
· SEC 10-Q — 10-Q discloses $3B share repurchase program authorized in April 2026, with $2.534B remaining as of June 30, 2026.
Key Events · Earnings and Guidance · REGN
-
Q2 Revenue and EPS Beat
Total revenues of $4.29B, up 17% YoY, and non-GAAP diluted EPS of $14.29, up 11% YoY, both significantly above consensus.
-
Dupixent Global Sales Hit $6B
Dupixent global net sales (recorded by Sanofi) reached a new all-time high of $6.0B, up 38% YoY, driven by strong demand and new indications.
-
EYLEA HD and Libtayo Surge
EYLEA HD U.S. net sales rose 52% to $596M; Libtayo global net sales grew 30% to $489M, both setting new records.
-
Sanofi Development Balance Fully Repaid
The Sanofi Development Balance was fully repaid as of Q2 2026, removing a drag on collaboration revenue and boosting profits starting Q3.
Analysis · REGN · Life Sciences
A massive Q2 beat saw Regeneron deliver revenue of $4.29B, 12% above consensus, and adjusted EPS of $14.29, nearly 40% above expectations. Dupixent global sales soared 38% to $6.0B, EYLEA HD U.S. sales jumped 52% to $596M, and Libtayo grew 30% to $489M. The Sanofi Development Balance was fully repaid, removing a drag on collaboration profits starting Q3. Full-year guidance for gross margin was raised, and R&D and SG&A ranges were tightened. This is a thesis-affirming quarter that demonstrates broad commercial momentum and pipeline progress, with approximately 50 clinical assets advancing.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REGN was trading at $717.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.9B. The 52-week trading range was $541.00 to $821.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.